login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

FDA clears expanded matrix of Glider PTCA balloon catheter


Tuesday, 17 Jul 2012 10:30
Glider
Glider

The US Food and Drug Administration (FDA) has given clearance to TriReme Medical for an expanded matrix of sizes for its Glider PTCA balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 – 3.5mm and in lengths from 4mm to 20mm. 


“Glider provides interventional cardiologists with an entirely new degree of control during the treatment of complex side branches and total occlusions,” said David Rizik, medical director and interventional cardiologist at Scottsdale Heart Group, Scottsdale, USA. “With its torqueable shaft and ultra short 4mm length, I am amased that such a clever design can provide such powerful clinical benefits. Glider has become my ‘go-to’ balloon when I approach the treatment of my most challenging cases.”

“Our recent experience in Europe demonstrates Glider’s ability to outperform conventional ‘best in class’ balloon catheters,” said Eitan Konstantino, president and CEO of TriReme Medical. “TriReme now has three product families that have received regulatory approval in the United States. I am proud of our development team that continues to bring to market ‘out-of-the-box’ solutions to simplify complex interventional procedures.”




Add New Comment

Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies
Friday, 31 Jul 2015
Abbott Vascular has announced it has entered into an agreement to purchase Tendyne Holdings (focused on developing minimally invasive mitral valve replacement therapies) and secured an option to ... Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies

Features


Bifurcation lesions: When a two-stent technique is needed
Tuesday, 18 Aug 2015
The advent of second-generation drug-eluting stents and the associated improved safety and efficacy has meant that the risks of using two stents for bifurcation lesions has significantly decreased. M... Bifurcation lesions: When a two-stent technique is needed

Getting to grips with social media
Tuesday, 04 Aug 2015
Pascal Meier believes that social media is the logical next step from the internet—just as the internet has revolutionised connectivity, social media is revolutionising communication. In this ... Getting to grips with social media

Profiles


Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions